Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for cbdMD in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.20.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in cbdMD. This rating has held steady since June 2022, when it changed from a Hold consensus rating.
cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. Its product categories include CBD tinctures, gummies, topical, and bath bombs. The company was founded by Caryn Dunayer on March 17, 2015 and is headquartered in Charlotte, NC.